Dr. Michael Gibson

About Michael Gibson

Education:

• Ph.D. in Clinical Investigation, Johns Hopkins Bloomberg School of Public Health, 2010.
• M.D., Johns Hopkins School of Medicine, Baltimore, Maryland, 1996.
• B.S., North Carolina State University, Raleigh, North Carolina, 1991.

Experience:

• Associate Professor of Medicine, Vanderbilt University.
• Director of Translational Research for Head and Neck Oncology, Vanderbilt-Ingram Cancer Center.
• Has held significant roles including Chairmanship at the Hillman Cancer Center Data, Safety and Monitoring Committee, and Medical Director of the University Hospitals Seidman Cancer Center Clinical Trials Unit.
• Renowned for advancing the treatment of aero-digestive cancers through translational research and clinical trials.

Area of expertise

Affiliated Hospitals

Vanderbilt University/Ingram Cancer Center

Vanderbilt University Medical Center

Clinical Trials Michael Gibson is currently running

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.

Recruiting1 award Phase 231 criteria

Chemotherapy + Radiotherapy

for Esophageal and Gastric Cancer

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.

Recruiting2 awards Phase 320 criteria

More about Michael Gibson

Other Doctors you might be interested in

Frequently asked questions